1. Merck Acquires Terns Pharma in $6.7B Deal, Betting Big on Leukemia Drug TERN-701
Merck is making a massive $6.7 billion bet on the future of cancer treatment, acquiring Terns Pharma in a deal that underscores the intense competition for promising oncology assets. The acquisition values Terns at $53 per share, a 6% premium over its previous closing price, but the real story is the staggering six-fol...